2023 - Research.com Medicine in Greece Leader Award
2022 - Research.com Medicine in Greece Leader Award
His research ties Eosinopenia and Immunology together. His research ties Immunology and Eosinopenia together. Borrowing concepts from CD34, Meletios A. Dimopoulos weaves in ideas under Antibody. Many of his studies involve connections with topics such as Stem cell and CD34. His Stem cell study frequently links to related topics such as Genetics. He regularly links together related areas like Neutralizing antibody in his Genetics studies. His studies link Virology with Neutralizing antibody. His research on Virology frequently connects to adjacent areas such as Vaccination. He combines Vaccination and Antibody in his research.
Meletios A. Dimopoulos connects Immunology with Lymphocyte in his study. His study connects Cohort and Internal medicine. In his research, he undertakes multidisciplinary study on Antibody and Gene. He incorporates Gene and Antibody in his research. His multidisciplinary approach integrates Multiple myeloma and Bortezomib in his work. His work often combines Bortezomib and Multiple myeloma studies. In his research, he performs multidisciplinary study on Disease and Immunity. While working in this field, Meletios A. Dimopoulos studies both Immunity and Vaccination. Borrowing concepts from Disease, Meletios A. Dimopoulos weaves in ideas under Vaccination.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)
International uniform response criteria for multiple myeloma
B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie.
British Journal of Haematology (2003)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos.
The New England Journal of Medicine (2008)
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Meletios Dimopoulos;Andrew Spencer;Michael Attal;H. Miles Prince.
The New England Journal of Medicine (2007)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)
Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
Aristotle Bamias;Efstathios Kastritis;Christina Bamia;Lia A. Moulopoulos.
Journal of Clinical Oncology (2005)
Hematological findings and complications of COVID-19.
Evangelos Terpos;Ioannis Ntanasis-Stathopoulos;Ismail Elalamy;Efstathios Kastritis.
American Journal of Hematology (2020)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel.
The New England Journal of Medicine (2016)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo.
The New England Journal of Medicine (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: